What is it?

Vitiligo is a chronic autoimmune skin condition in which the immune system destroys melanocytes (the cells responsible for producing skin pigment), resulting in well-defined, milk-white patches of depigmented skin. It affects approximately 0.5-2% of the population worldwide (roughly 1 in 50 to 1 in 200 individuals). While vitiligo is not physically painful or dangerous, it can have a significant psychological impact, particularly in individuals with darker skin tones where the contrast is more visible.

Who is affected?

Vitiligo can affect anyone, regardless of skin color or ethnicity:

Prevalence: Affects 0.5-2% of the global population, with no significant variation between ethnic groups
Age: Approximately 50% of cases appear before age 20, with peak onset between 10 and 30 years. Can occur at any age, including infancy
Gender: Affects men and women equally, although women seek treatment more frequently
Family history: Approximately 20-30% of patients have a family member with vitiligo. Over 50 genetic susceptibility loci have been identified, confirming a polygenic inheritance pattern
Autoimmune associations: Frequently associated with other autoimmune conditions — thyroid disease (14% of patients), alopecia areata, type 1 diabetes, and pernicious anemia. Screening for thyroid disease is recommended

What causes it?

Vitiligo results from autoimmune destruction of melanocytes through multiple interacting mechanisms:

Autoimmune mechanism: CD8+ cytotoxic T cells target and destroy melanocytes. This is supported by the association with other autoimmune diseases and response to immunosuppressive treatments
Genetic susceptibility: Polygenic, with over 50 susceptibility loci identified — many shared with other autoimmune diseases. Family history is positive in 20-30% of patients
Oxidative stress: Melanocytes in vitiligo patients show increased vulnerability to reactive oxygen species, leading to cellular damage
Triggers: Physical trauma (Koebner phenomenon), severe sunburn, emotional stress, and chemical exposure (phenolic compounds) can precipitate or worsen the disease

What are the clinical features?

Vitiligo presents with characteristic depigmented patches:

Signs:

Depigmented macules and patches (milk-white, well-defined borders, round to irregular shape, ranging from millimeters to large body areas)
Leukotrichia (white hair within depigmented patches, indicating melanocyte loss in hair follicles — a marker of more resistant disease)
Koebner phenomenon (new patches appearing at sites of skin trauma, friction, or sunburn)
Enhanced visibility under Wood's lamp (depigmented areas fluoresce bright blue-white under UV light, helpful for detecting early or subtle lesions in fair-skinned individuals)

Common distribution patterns:

Non-segmental vitiligo (the most common form, bilateral and symmetric — affecting face, hands, feet, knees, elbows, and body folds)
Acrofacial pattern (hands, feet, and perioral area — a subtype of non-segmental vitiligo)
Segmental vitiligo (unilateral, following a dermatomal distribution — earlier onset, rapid stabilization, less associated with autoimmune disease)
Universal vitiligo (more than 80% of body surface depigmented — rare)

Symptoms:

Usually asymptomatic — the depigmented patches do not cause pain or itching in most cases
Sunburn susceptibility (depigmented skin lacks melanin protection and burns easily)
Psychological distress (anxiety, depression, social stigma, reduced self-esteem — reported in up to 75% of patients)

How is it diagnosed?

Diagnosis is primarily clinical:

Clinical examination: Characteristic milk-white, well-defined depigmented patches in typical distribution
Wood's lamp examination: Enhances contrast of depigmented areas, especially useful in fair skin and for detecting early lesions
Disease activity assessment: VIDA score (Vitiligo Disease Activity) grades activity from 0 (stable for over 1 year) to 4 (actively spreading). VASI score (Vitiligo Area Scoring Index) quantifies extent
Laboratory screening: Thyroid function tests and anti-TPO antibodies (due to frequent thyroid autoimmune association), fasting glucose
Skin biopsy: Rarely needed — reserved for atypical presentations or when differential diagnosis is unclear
Differential diagnosis: Pityriasis alba, tinea versicolor, post-inflammatory hypopigmentation, chemical leukoderma, lichen sclerosus

What treatment options are available?

Treatment depends on disease extent, activity, and location:

Topical therapy (for limited disease, <10% body surface area):
- Topical corticosteroids (first-line for localized vitiligo — applied in cycles to minimize side effects)
- Calcineurin inhibitors (tacrolimus 0.1% ointment, pimecrolimus 1% cream — preferred for face and skin folds, no risk of atrophy)
- Ruxolitinib cream 1.5% (Opzelura — first FDA-approved treatment for vitiligo, a JAK1/JAK2 inhibitor, applied twice daily)
Phototherapy (for more extensive disease):
- Narrowband UVB (NB-UVB) — the most effective phototherapy modality, requiring 2-3 sessions per week for at least 6-12 months
- Excimer laser (308nm) — targeted phototherapy for limited areas, particularly effective for face and neck
Systemic therapy (for rapidly progressive disease):
- Oral mini-pulse corticosteroids (dexamethasone 2.5mg on 2 consecutive days per week — to stabilize active disease, not for repigmentation)
Surgical options (for stable, localized, treatment-resistant vitiligo):
- Melanocyte transplantation and epidermal cell suspension
- Punch grafting
Depigmentation (for extensive vitiligo affecting >50% of body surface):
- Monobenzone cream — permanent depigmentation of remaining pigmented skin for cosmetic uniformity
Supportive care:
- Sun protection (SPF 50+) for depigmented areas
- Camouflage cosmetics for visible areas
- Psychological support — counseling or peer support groups

Key points for patients

Vitiligo is an autoimmune condition, not contagious and not caused by infection
Repigmentation is a slow process — visible improvement typically requires 3-6 months of consistent treatment, with best results on the face and worst on hands and feet
Early treatment of new patches yields better outcomes
Sun protection is essential — depigmented skin burns easily and does not tan
Request thyroid function screening, as thyroid autoimmune disease is common in vitiligo patients
The psychological impact is real and valid — seek professional support if needed
New treatments (ruxolitinib cream) represent a significant advance in vitiligo therapy